Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting
Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting
The live webcast can be accessed through Kura Oncology's website and in the Investors section shortly before the event.Kura Oncology will host a virtual investor event on December 9 to discuss ziftomenib's clinical trial updates.
Kura Oncology将于12月9日举办虚拟投资者活动，讨论ziftomenib的临床试验更新。
Quiver AI Summary
Quiver AI 概要
Kura Oncology, Inc. announced a virtual investor event set for December 9, 2024, at 8:00 a.m. ET to discuss its KOMET-007 clinical trial for the oral menin inhibitor, ziftomenib, following new data presented at the ASH Annual Meeting. The event will feature the management team and trial investigators, and interested parties can join via phone or webcast. Kura's pipelines focus on precision medicines for cancer, with ziftomenib recognized by the FDA as a Breakthrough Therapy for a specific type of leukemia. The company has also entered a global collaboration with Kyowa Kirin for ziftomenib's development and is planning a New Drug Application submission in 2025. Other drug candidates are in various stages of clinical trials for different cancers.
Kura oncology公司宣布将于2024年12月9日上午8:00举行虚拟投资者活动，讨论口服Menin抑制剂ziftomenib的KOMEt-007临床试验最新数据，这些数据是在ASH年会上展示的。活动将邀请管理团队和试验研究员参加，有兴趣的方可以通过电话或网络直播参与。Kura的产品线侧重于癌症的精准医疗，其ziftomenib被FDA认可为特定类型白血病的突破性疗法。公司还与協和麒麟全球合作开发ziftomenib，并计划在2025年提交新药申请。其他药物候选品正在为不同的癌症进行临床试验。
Potential Positives
潜在的积极因素
- The announcement of a virtual investor event demonstrates Kura Oncology's commitment to transparency and engagement with stakeholders regarding its clinical developments.
- Ziftomenib has received Breakthrough Therapy Designation from the FDA, highlighting its potential significance in the treatment of relapsed/refractory NPM1-mutant acute myeloid leukemia.
- The global strategic collaboration agreement with Kyowa Kirin for ziftomenib indicates strong industry partnerships, potentially enhancing development and commercialization efforts.
- Completion of enrollment in the Phase 2 registration-directed trial of ziftomenib positions the company well for a New Drug Application submission anticipated in 2025, suggesting progress in their drug development pipeline.
- Kura Oncology宣布举办虚拟投资者活动，展示了其在临床发展方面与利益相关者交流透明度和参与度的承诺。
- FDA已授予ziftomenib突破性疗法认定，凸显其在治疗复发/难治性NPM1基因突变急性髓样白血病中的潜在重要性。
- 与協和麒麟达成的全球战略合作协议为ziftomenib标志着强大的行业合作伙伴关系，有望增强开发和商业化工作。
- 完成ziftomenib第2期注册导向试验的招募，为预期在2025年提交新药申请的公司提供了良好的定位，表明其药物开发管线取得了进展。
Potential Negatives
潜在负面影响
- The announcement of a virtual investor event may indicate a lack of in-person engagement opportunities, which can be perceived as a weakness in corporate transparency and stakeholder communication.
- The timing of the event, shortly after the ASH Annual Meeting, could suggest that the company is attempting to manage expectations regarding the reception and implications of their clinical data.
- While Kura announced a strategic collaboration with Kyowa Kirin, the partnership might raise concerns regarding reliance on external companies for development and commercialization efforts, potentially impacting the company's control over its pipeline.
- 虚拟投资者活动的公告可能表明缺少面对面参与机会，这可能被视为公司透明度和利益相关者沟通方面的弱点。
- 活动时间紧随ASH年会之后，可能暗示公司试图管理对其临床数据接受和影响的预期。
- 虽然kura oncology宣布与京都制药的战略合作，但该合作可能引发对依赖外部公司进行开发和商业化努力的担忧，可能影响公司对其产品线的控制。
FAQ
常见问题
What is the date and time of Kura Oncology's virtual investor event?
Kura Oncology的虚拟投资者活动日期和时间是什么？
Kura Oncology's virtual investor event is scheduled for December 9, 2024, at 8:00 a.m. ET / 5:00 a.m. PT.
kura oncology虚拟投资者活动定于2024年12月9日上午8:00 Et / 上午5:00 Pt。
How can I access the live webcast for the KOMET-007 trial discussion?
我如何访问KOMEt-007试验讨论的现场网络广播？
The live webcast can be accessed through Kura Oncology's website and in the Investors section shortly before the event.
可以通过kura oncology的网站访问现场网络直播，并在活动开始前不久进入投资者部分。
What is ziftomenib, and what is its significance?
ziftomenib是一种口服的、选择性的menin抑制剂，也是第一种被授予突破治疗标志的调查性治疗，用于复发/难治性NPM1突变AML，其意义是什么？
Ziftomenib is an oral, selective menin inhibitor and the first investigational therapy with Breakthrough Therapy Designation for relapsed/refractory NPM1-mutant AML.
ziftomenib是一种口服的、选择性的menin抑制剂，也是第一种被授予突破治疗标志的调查性治疗，用于复发/难治性NPM1突变AML。
What clinical trials is Kura conducting with ziftomenib?
Kura正在进行哪些临床试验，以评估ziftomenib？
Kura is conducting trials to evaluate ziftomenib in various settings, including combination therapies for newly diagnosed and relapsed/refractory AML.
Kura正在进行试验，评估ziftomenib在各种情境下的应用，包括新诊断和复发/难治性AML的联合疗法。
Who can I contact for investor relations at Kura Oncology?
谁可以联系Kura oncology的投资者关系？
You can contact Pete De Spain, Executive Vice President, Investor Relations, at (858) 500-8833 or pete@kuraoncology.com.
您可以联系Pete De Spain，执行副总裁，投资者关系，电话：(858) 500-8833，或邮箱：pete@kuraoncology.com。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$KURA Insider Trading Activity
kura oncology内幕交易活动
$KURA insiders have traded $KURA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
kura oncology内部人士在过去6个月中已经进行了1次开放市场交易。其中，有0次购买和1次销售。
Here's a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
这是$KURA股票内部人员在过去6个月中最近交易的详细情况:
- KATHLEEN FORD (Chief Operating Officer) sold 526 shares.
- KATHLEEN FORD（首席营运官）卖出了526股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟踪内部交易，请查看Quiver Quantitative的内部交易特斯拉-仪表。
$KURA Hedge Fund Activity
kura oncology对冲基金活动
We have seen 81 institutional investors add shares of $KURA stock to their portfolio, and 86 decrease their positions in their most recent quarter.
我们已经看到81家机构投资者在他们的投资组合中增加了$KURA股票的持股，而86家在最近一个季度减少了它们的持仓。
Here are some of the largest recent moves:
以下是一些最近最大的交易动态：
- ARTAL GROUP S.A. removed 1,819,884 shares (-100.0%) from their portfolio in Q3 2024
- DEEP TRACK CAPITAL, LP added 1,578,749 shares (+410.3%) to their portfolio in Q3 2024
- BVF INC/IL removed 710,276 shares (-17.4%) from their portfolio in Q3 2024
- ASSENAGON ASSET MANAGEMENT S.A. removed 679,514 shares (-39.2%) from their portfolio in Q3 2024
- SUVRETTA CAPITAL MANAGEMENT, LLC added 583,155 shares (+8.2%) to their portfolio in Q3 2024
- SOFINNOVA INVESTMENTS, INC. removed 528,359 shares (-64.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 505,712 shares (+149.0%) to their portfolio in Q3 2024
- ARTAL GROUP S.A.在2024年第三季度将1,819,884股股票（-100.0%）从其投资组合中移除
- DEEP TRACk CAPITAL, LP在2024年第三季度将1,578,749股股票（+410.3%）添加到其投资组合中
- BVF INC/IL在2024年第三季度将710,276股股票（-17.4%）从其投资组合中移除
- ASSENAGON资产管理SA在2024年第三季度将679,514股股票（-39.2%）从其投资组合中移除
- SUVRETTA CAPITAL MANAGEMENt, LLC在2024年第三季度将583,155股股票（+8.2%）添加到其投资组合中
- SOFINNOVA INVESTMENTS, INC.在2024年第三季度将528,359股股票（-64.0%）从其投资组合中移除
- MILLENNIUm MANAGEMENt LLC在2024年第三季度将505,712股股票（+149.0%）添加到其投资组合中
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追踪对冲基金的股票组合，请查看Quiver Quantitative的机构持股仪表板。
Full Release
全面发布
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66
th
American Society of Hematology (ASH) Annual Meeting in San Diego.
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. Et / 5:00 a.m. Pt on Monday, December 9, 2024, to discuss the KOMEt-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66
楼
American Society of Hematology (ASH) Annual Meeting in San Diego.
The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available
here
and in the Investors section of Kura's website, with an archived replay available shortly after the event.
The virtual event will feature members of the management team along with investigators from the KOMEt-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available
这里
and in the Investors section of Kura's website, with an archived replay available shortly after the event.
About Kura Oncology
关于kura oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at
and follow us on
X
and
LinkedIn
.
kura oncology是一家临床阶段的生物制药公司，致力于实现癌症治疗的精准药物的承诺。该公司的产品线包括针对癌症信号通路的小分子药物候选。Ziftomenib是一种每日一次的口服menin抑制剂，是第一款并且唯一一款正在进行研究的疗法，获得了美国食品和药物管理局针对复发/难治性（R/R）NPM1基因突变急性髓样白血病（AML）治疗的突破性疗法认定。2024年11月，Kura与协和鸣人株式会社达成全球战略合作协议，共同开发和商业化ziftomenib用于AML和其他血液恶性肿瘤。在复发/难治性NPM1突变AML中ziftomenib的2期注册导向试验招募已经完成，公司预计将于2025年提交新药申请。Kura还在进行一系列临床试验，评估ziftomenib与目前治疗标准联合治疗新诊断和复发/难治性NPM1突变和KMT2A重排AML。KO-2806是一种次世代法尼酰转移酶抑制剂，正在评估其在1期剂量递增试验中作为单药治疗以及与靶向治疗联合使用。Tipifarnib是一种有效且选择性的FTI，目前正在与alpelisib联合进行1/2期试验，用于PIK3CA依赖性头颈鳞状细胞癌患者。有关更多信息，请访问Kura的网站：
并关注我们
X
和
LinkedIn
.
Kura Contacts
kura oncology 联系人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投资者:
Pete De Spain
执行副总裁，投资者关系
企业通讯
858-500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒体:
Cassidy McClain
副总裁
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
